Carbapenem Market Report 2025 (Global Edition)

Global Carbapenem Market Report 2024 Market Size Split by Drug Class Outlook: (Meropenem, Imipenem, Ertapenem, Others), by Application Outlook: (Urinary Tract Infections, Bloodstream Infections, Intra...

Carbapenem Market Report Description

We have various report editions of Carbapenem Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Carbapenem Market Insights Video

Competitive Landscape of the Carbapenem Market

There are a number of large international enterprises as well as smaller to medium-sized businesses vying for market share in the competitive carbapenem industry. The ongoing release of novel products that make use of a variety of technologies is a crucial component of market strategy. In this ever-changing environment, notable industrial leaders wield significant influence and frequently propel breakthroughs through large investments in R&D. Strategic partnerships, mergers, and acquisitions are also crucial for strengthening market positions and broadening worldwide reach in the face of changing regulatory environments.

May 2023: Healthy participants were given the first dosage of antibiotic medication for hospital-acquired infections as part of Antabio's Phase I experiment. The treatment, called MEM-ANT3310, combines Antabio's new broad-spectrum serine beta-lactamase inhibitor, ANT3310, with meropenem (MEM). (Source: https://www.clinicaltrialsarena.com/news/antabio-on-quest-to-tackle-antibiotic-resistance/ ) May 2023: The U.S. Food and Drug Administration has approved the new medication Xacduro (sulbactam for injection; durlobactam for injection) for use in treating ventilator-associated bacterial pneumonia (VABP) and hospital-acquired bacterial pneumonia (HABP) in patients aged 18 and up. These infections are brought on by susceptible strains of the Acinetobacter baumannii-calcoaceticus complex. (Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria ) September 2022: GSK plc. and Spero Therapeutics reached an exclusive licensing agreement for the commercialization of Tebipenem HBr, a late-stage antibiotic, with the exception of Japan and a few other Asian countries. Therefore, it is anticipated that the development and promotion of new carbapenems to treat bacterial infections will accelerate market growth. (Source: https://www.gsk.com/en-gb/media/press-releases/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections/ )

Top Companies Market Share in Carbapenem Industry: (In no particular order of Rank)

• Spero Therapeutics Inc.
• Savior Lifetec Corporation
• Meiji Seika Pharma Co. Ltd.
• Merck & Co. Inc.
• Gland Pharma Ltd. (Fosun Pharmaceutical Co. Ltd.)
• Aurobindo Pharma Ltd.
• Daewoong Pharmaceutical Co.
• Ltd.
• Iterum Therapeutics plc
• ACS Dobfar S.P.A.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Carbapenem Market

Which Region Dominates the Carbapenem Market in 2024?

According to Cognitive Market Research, North America currently dominates the Carbapenem market, and the region is expected to have significant growth during the projected period. The market is expanding in the region because of the high rate of urinary tract infections and other bacterial inflammation, as well as the presence of sophisticated medical facilities and a strong healthcare infrastructure. It is also expected that the existence of important players will support the market's expansion. For instance, the U.S. FDA authorized RECARBIO (imipenem, cilastatin, and relebactam) in June 2020 for the treatment of respiratory and hospital-acquired pneumonia in adults (HABP/VABP).

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). This growth may be attributed to a variety of factors, such as the growing number of elderly people, restricted access to healthcare services, and dense urbanization. In the Asia-Pacific region, the high incidence of community-acquired pneumonia has turned into a financial hardship. JW Pharmaceutical Corp. made a big statement in June 2021 about the distribution of their ertapenem API-based antibiotic in the United States, which is produced by Gland Pharma in India. This achievement would be a significant turning point for the Korean business and is anticipated to be a key factor in propelling its future expansion into new markets.

The current report Scope analyzes Carbapenem Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Carbapenem

According to Cognitive Market Research, the global Carbapenem market size was estimated at USD 4152.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1661.04 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Carbapenem market with a market size of USD 1310.56 million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period ascribed to the sophisticated healthcare system and high prevalence of bacterial illnesses.
• The Canada Carbapenem market had a market share of USD 199.32 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period because of the growing burden of infectious diseases, growing awareness of antibiotic resistance, and rising healthcare costs.
• The Mexico Carbapenem market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 151.15 million in 2024.

Europe Carbapenem

According to Cognitive Market Research, the global Carbapenem market size was estimated at USD 4152.6 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1245.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031.

• The United Kingdom Carbapenem market had a market share of USD 209.29 million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period because of better medical facilities and increased attention to the fight against infectious diseases.
• The France Carbapenem market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 114.61 million in 2024.
• According to Cognitive Market Research, the German Carbapenem market size was valued at USD 246.66 million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period because to advancements in research and development, the increased frequency of antibiotic prescriptions, and the expanding use of carbapenem-based antibiotics.
• The Italy Carbapenem market is projected to witness growth at a CAGR of 2.9% during the forecast period, with a market size of USD 107.14 million in 2024.
• The Russia Carbapenem market is projected to witness growth at a CAGR of 2.5% during the forecast period, with a market size of USD 193.10 million in 2024.
• The Spain Carbapenem market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 102.15 million in 2024
• The Luxembourg Carbapenem market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 38.26 million in 2024.
• The Portugal Carbapenem market is projected to witness growth at a CAGR of 3.3% during the forecast period, with a market size of USD 26.16 million in 2024.
• The Greece Carbapenem market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 14.95 million in 2024.
• The Rest of Europe's Carbapenem market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 193.10 million in 2024.

Asia Pacific Carbapenem

According to Cognitive Market Research, the global Carbapenem market size was estimated at USD 4152.6 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 955.10 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Carbapenem market size was valued at USD 429.79 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period attributed to the high frequency of bacterial infections and the advanced healthcare system.
• The Japan Carbapenem market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 131.80 million in 2024.
• The India Carbapenem market had a market share of USD 114.61 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period due to the rising expenses of healthcare, the increasing burden of infectious diseases, and the growing understanding of antibiotic resistance.
• The South Korean Carbapenem market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 95.51 million in 2024.
• The Australian Carbapenem market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 49.67 million in 2024.
• The South East Asia Carbapenem market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 65.90 million in 2024.
• The Rest of Asia Pacific Carbapenem market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 67.81 million in 2024.

South America Carbapenem

According to Cognitive Market Research, the global Carbapenem market size was estimated at USD 4152.6 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 207.63 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Carbapenem market size was valued at USD 88.87 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period due to improved healthcare facilities and heightened awareness of the need to combat infectious diseases.
• Argentina's Carbapenem market had a market share of USD 34.88 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period due to the growing use of carbapenem-based antibiotics, the rise in the number of antibiotic prescriptions, and improvements in research and development.
• Colombia Carbapenem market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 18.48 million in 2024.
• Peru Carbapenem market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 17.03 million in 2024.
• Chile Carbapenem market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 14.95 million in 2024.
• The Rest of Latin America's Carbapenem market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 33.43 million in 2024.

Middle East and Africa Carbapenem

According to Cognitive Market Research, the global Carbapenem market size was estimated at USD 4152.6 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 83.05 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031..

• The GCC Countries Carbapenem market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 35.55 million in 2024 ascribed to the sophisticated healthcare system and the high incidence of bacterial illnesses.
• The Egypt Carbapenem market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 8.72 million in 2024.
• The South Africa Carbapenem market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 13.12 million in 2024 because of the growing burden of infectious diseases, the rising costs of healthcare, and our growing knowledge of antibiotic resistance.
• The Turkey Carbapenem market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 7.14 million in 2024.
• The Nigeria Carbapenem market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 8.72 million in 2024.
• The Rest of the MEA Carbapenem market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 9.80 million in 2024.

Carbapenem Market Analysis

How are Segments Performing in the Global Carbapenem Market?

Carbapenem Market Drug Class Segment Analysis

According to Cognitive Market Research, Meropenem category is likely to dominate the Carbapenem Market over the forecast period. The necessity for efficient therapies to combat extreme inflammation and the growing incidence of bacteria resistant to antibiotics drove the need for meropenem antibiotics. Meropenem is also frequently seen in hospital formularies, which are listings of drugs that have been authorized for use in medical facilities. In order to produce and market Vaborem (meropenem and vaborbactam) in China, the Menarini Group and SciClone Pharmaceuticals (Holdings) Limited entered into an exclusive licensing deal in September 2022. With an emphasis on carbapenem-resistant Enterobacterales (CRE) infections, this strategic partnership seeks to increase the variety of treatment options available to address the growing public health challenge of antimicrobial-resistant infections.

The Ertapenem is the fastest-growing segment in the Carbapenem Market. With its once-daily dosage schedule, ertapenem provides a special benefit that enhances patient compliance and makes it especially practical for outpatient settings. Ertapenem's pharmacokinetic characteristics has made it a desirable treatment choice for complex infections, such as those affecting the abdominal cavity and urinary system. Its specialized application and flexible dosing schedule help to maintain its strong market presence even though its spectrum is more limited than that of other carbapenems.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Carbapenem Industry. Request a Free Sample PDF!

Carbapenem Market Application Segment Analysis

According to Cognitive Market Research, the Urinary Tract Infections segment holds the largest share of the market. One of the most common bacterial inflammations, UTIs impact millions of individuals annually all over the world. Given that over half of women will get a UTI at some point in their life, they are especially common among them. Because of their high frequency, they have a leading position in terms of total bacterial inflammation. The market is expected to be impacted by the increasing number of clinical trials examining carbapenems for the treatment of UTIs. For instance, a phase III study published in April 2022 showed that the investigational oral antibiotic tebipenem pivoxil hydrobromide was as effective as intravenous ertapenem in treating hospitalized patients with acute pyelonephritis or complicated UTIs.

In the Carbapenem Market, the Intra-abdominal Infections has been expanding at a rapid pace. Intra-abdominal infections, which are frequently brought on by trauma or surgery, can be very difficult to treat, especially if the microorganisms causing them are resistant. Because carbapenems are effective against a variety of bacterial species and have a broad spectrum of action, they are commonly used in these situations. This application segment is growing as a result of the rising number of surgical procedures and the corresponding risk of infections, underscoring the critical role carbapenem antibiotics play in treating these complicated problems.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Carbapenem Distribution Channel Outlook: Segment Analysis

Carbapenem Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the Hospital Pharmacies segment holds the largest market share. Hospital healthcare providers including intensivists and infectious disease experts frequently prescribe carbapenem-based medicines. Furthermore, in order to stop the spread of resistant germs and inflammation linked to healthcare, hospitals maintain stringent infection control procedures. Hospital pharmacies are the main source of carbapenems, which are essential medicines for treating this kind of inflammation.

In the Carbapenem market, the rapidly growing sector is the Retail Pharmacies category because bacterial illnesses are becoming more common worldwide and because antibiotics are becoming more widely available for outpatient treatment. Because they are easily accessible to patients, retail pharmacies are an essential distribution channel, especially in urban and semi-urban areas. The demand for carbapenems, which are frequently recommended for severe bacterial infections, has increased due to increased knowledge of multi-drug resistant diseases.

• Hospital Pharmacies
• Retail Pharmacies
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion